Retrospective Comparison of Initial vs. Subsequent Simultaneous Side-by-Side Stenting with Uncovered Metal Stents during Endoscopic Retrograde Cholangiopancreatography for Unresectable Malignant Hilar Biliary Obstructions.

IF 2
Koji Takahashi, Hiroshi Ohyama, Motoyasu Kan, Mayu Ouchi, Hiroki Nagashima, Kohichiroh Okitsu, Izumi Ohno, Naoya Kato
{"title":"Retrospective Comparison of Initial vs. Subsequent Simultaneous Side-by-Side Stenting with Uncovered Metal Stents during Endoscopic Retrograde Cholangiopancreatography for Unresectable Malignant Hilar Biliary Obstructions.","authors":"Koji Takahashi, Hiroshi Ohyama, Motoyasu Kan, Mayu Ouchi, Hiroki Nagashima, Kohichiroh Okitsu, Izumi Ohno, Naoya Kato","doi":"10.15403/jgld-5933","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>This study aimed to evaluate the efficacy and safety of transpapillary simultaneous side-by-side (SBS) stenting using uncovered self-expandable metal stents (UCSEMSs) at the initial endoscopic retrograde cholangiopancreatography (ERCP) for unresectable malignant hilar biliary obstruction (UMHBO).</p><p><strong>Methods: </strong>A total of 67 patients with UMHBO who underwent simultaneous SBS stenting at our institution were retrospectively divided into two groups: the SBS stenting at the initial ERCP group (n=13) and the SBS stenting at the subsequent ERCP group (n=54). Clinical outcomes were compared between the groups.</p><p><strong>Results: </strong>There were no significant differences between the SBS stenting at the initial ERCP group and the SBS stenting at the subsequent ERCP group in procedural time (median: 50 vs. 40 minutes, p=0.31), functional success rate (69.2% vs. 83.3%, p=0.25), adverse event rate (30.8% vs. 14.8%, p=0.18), recurrent biliary obstruction (RBO) rate (23.1% vs. 38.9%, p=0.29), technical success rate of re-intervention (100% vs. 90.5%, p=0.58), cumulative time to RBO (not reached vs. 252 days, p=0.80), or median overall survival (73 vs. 212 days, p=0.12).</p><p><strong>Conclusions: </strong>Simultaneous SBS stenting using UCSEMSs at the initial ERCP is a safe and effective strategy for managing UMHBO, with outcomes comparable to those of SBS stenting performed at the subsequent ERCP.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"214-219"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastrointestinal and liver diseases : JGLD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15403/jgld-5933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: This study aimed to evaluate the efficacy and safety of transpapillary simultaneous side-by-side (SBS) stenting using uncovered self-expandable metal stents (UCSEMSs) at the initial endoscopic retrograde cholangiopancreatography (ERCP) for unresectable malignant hilar biliary obstruction (UMHBO).

Methods: A total of 67 patients with UMHBO who underwent simultaneous SBS stenting at our institution were retrospectively divided into two groups: the SBS stenting at the initial ERCP group (n=13) and the SBS stenting at the subsequent ERCP group (n=54). Clinical outcomes were compared between the groups.

Results: There were no significant differences between the SBS stenting at the initial ERCP group and the SBS stenting at the subsequent ERCP group in procedural time (median: 50 vs. 40 minutes, p=0.31), functional success rate (69.2% vs. 83.3%, p=0.25), adverse event rate (30.8% vs. 14.8%, p=0.18), recurrent biliary obstruction (RBO) rate (23.1% vs. 38.9%, p=0.29), technical success rate of re-intervention (100% vs. 90.5%, p=0.58), cumulative time to RBO (not reached vs. 252 days, p=0.80), or median overall survival (73 vs. 212 days, p=0.12).

Conclusions: Simultaneous SBS stenting using UCSEMSs at the initial ERCP is a safe and effective strategy for managing UMHBO, with outcomes comparable to those of SBS stenting performed at the subsequent ERCP.

内镜逆行胆管造影治疗不可切除的恶性胆道门部梗阻时,首次与随后同时放置未覆盖金属支架的回顾性比较。
背景和目的:本研究旨在评估在初始内镜逆行胆管造影(ERCP)中使用无盖自膨胀金属支架(UCSEMSs)进行经毛细血管同时并排(SBS)支架治疗不可切除的恶性肝门胆道梗阻(UMHBO)的有效性和安全性。方法:回顾性将67例在我院同时行SBS支架置入的UMHBO患者分为两组:首次ERCP组SBS支架置入组(n=13)和随后ERCP组(n=54)。比较两组临床结果。结果:初始ERCP组SBS支架置入与后续ERCP组SBS支架置入在手术时间上无显著差异(中位数:50 vs. 40分钟,p=0.31),功能成功率(69.2% vs. 83.3%, p=0.25),不良事件发生率(30.8% vs. 14.8%, p=0.18),复发性胆道梗阻(RBO)率(23.1% vs. 38.9%, p=0.29),再干预技术成功率(100% vs. 90.5%, p=0.58),累计到RBO时间(未达到vs. 252天,p=0.80),或中位总生存期(73 vs. 212天,p=0.12)。结论:在最初的ERCP中使用UCSEMSs同时置入SBS支架是一种安全有效的治疗UMHBO的策略,其结果与在随后的ERCP中使用SBS支架的结果相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信